A drug built to help brain cells clear out their damaged power units has now been given to its first person with Parkinson's disease, but the trial is not designed to show whether it helps.
According to Longevity.Technology's report, the British company Mission Therapeutics has dosed the first patient in a Phase 1b study of MTX325. The patient was treated at the Royal Liverpool University Hospital in the UK. This article is based on that report. The company announcement and the underlying research papers were not reviewed. Here is the idea. Mitochondria are the parts of a cell that produce its energy. They wear out. Cells have a cleanup process, called mitophagy, that removes the damaged ones. Mitochondrial decline is widely studied as one of the biological changes that come with aging, and the report says Parkinson's is one of the diseases where it is suspected to play a role.
According to the report, MTX325 is a first-in-class pill that can enter the brain. It blocks USP30, an enzyme found on mitochondria. USP30 acts as a brake on mitophagy. By releasing that brake, the drug is designed to improve clearance of dysfunctional mitochondria, support cell health and reduce inflammation. The company says this could slow or stop the processes thought to drive Parkinson's progression. That is the company's claim, not a result.
The supporting evidence described so far comes from animals and early human work. Longevity.Technology says a study in Nature Communications found that deleting the gene for USP30 protected dopamine-producing neurons in a mouse model of Parkinson's. The company says MTX325 produced a similar result in the same model. In its own preclinical studies, it reports increased mitophagy and beneficial effects on alpha-synuclein, a protein that builds up in Parkinson's, and on the dopamine cells the disease targets. Mouse models do not always predict what happens in people.
In humans, the report says an earlier Phase 1a study in healthy volunteers is completed. According to the company, the drug showed high penetration into the central nervous system, and a PET scan study confirmed it reaches brain tissue. Reaching the brain is a necessary step. It does not show the drug works.
The new study, called MTX325-101, will enroll 36 people with mild to moderate idiopathic Parkinson's in the UK, Europe and Australia. Recruitment is ongoing. According to the report, its stated goal is clinical proof-of-mechanism: checking whether the drug does in people what it does in the lab. Researchers will assess biological responses using biomarkers and imaging, alongside safety and tolerability. The report describes this as a more modest question than whether patients feel better.
That is why this trial cannot yet show benefit. A small study built to test biological activity and safety is not built to show that symptoms improve or that the disease slows. A positive result would mean the drug engages its target in people. A negative result would suggest the lab findings may not carry over. Either outcome would help guide decisions about larger trials. Mission's Chief Medical Officer, Dr Suhail Nurbhai, said the drug has the potential to move "beyond management of symptoms offered by current therapies." The report notes the company is backed by investors including Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund and SR One.
The report also frames a wider question. If helping cells clear worn-out parts benefits neurons in Parkinson's, the same logic could be tested in other age-related conditions. For now, that remains a hypothesis.
A data readout from the trial is expected in late 2027, and it will show whether MTX325 acts on its target in people with Parkinson's. Anyone with Parkinson's or concerns about it should not start or stop any treatment without talking to their own clinician.
Source: Longevity.Technology
Read the cited source: Source 1
Keep reading on this subject
Mitochondria · Autophagy & cellular cleanup · Brain health & cognition